Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

Inclusion Criteria: * Understand and sign an informed consent form * Males will agree to use an approved double-barrier method of contraception from Day 1 until 1 month after study completion * Subject tests negative on urine drug test unless the subject has a prescription for the drug(s) that test positive Exclusion Criteria: * Subjects under opioid therapy for cancer-related pain or for the management of drug addiction * Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other active medical disorders associated with diarrhea, intermittent loose stools, or constipation * Subjects who have participated in any other investigational drug study within 30 days prior to Day 1 * Prior exposure to S-297995